Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07170267

Transversalis Fascia Plane Block Versus Intrathecal Dexmedetomidine in Patients Undergoing Cesarean Section

Analgesic Efficacy of Transversalis Fascia Plane Block Versus Intrathecal Dexmedetomidine in Patients Undergoing Cesarean Section: A Randomized Controlled Trial

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Tanta University · Academic / Other
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

This study aims to compare the analgesic efficacy of the transversalis fascia plane (TFP) block and intrathecal dexmedetomidine in patients undergoing cesarean section (CS).

Detailed description

Cesarean section (CS) is a commonly performed major surgical procedure that results in substantial postoperative pain and patient dissatisfaction. Spinal anesthesia is commonly used in CS surgery. However, it may be associated with several side effects, particularly hypotension. Dexmedetomidine is an α2 adrenergic receptor agonist that has an analgesic effect. Ultrasound-guided interfascial plane blocks are often used in multimodal analgesia regimens. Local anaesthetic injection into the transversalis fascia plane (TFP) anesthetizes the proximal branches of T12 and L1 which targeted in the plane between the transversus abdominis muscle and the transversalis fascia.

Conditions

Interventions

TypeNameDescription
OTHERTransversalis fascia plane blockPatients will receive spinal anesthesia (using 2.5 mL of hyperbaric bupivacaine 0.5%) with bilateral transversalis fascia plane (TFP) block (using 20 mL of bupivacaine 0.25%) at the end of surgery.
DRUGIntrathecal dexmedetomidinePatients will receive spinal anesthesia (using 2.5 mL of hyperbaric bupivacaine 0.5%) + (5 µg intrathecal dexmedetomidine diluted in 0.5ml saline) with a sham block at the end of surgery.

Timeline

Start date
2025-09-13
Primary completion
2026-03-01
Completion
2026-03-01
First posted
2025-09-12
Last updated
2025-09-16

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT07170267. Inclusion in this directory is not an endorsement.